Pristine invaginated mesostructured hollow carbon spheres (IMHCSs) were shown in 2017 to act as low-toxicity vaccine adjuvants that outperform the saponin adjuvant QuilA in humoral (antibody) immunization but bias T-helper responses toward Th2 and show weaker cell-mediated (Th1) cytokine responses; the mechanistic link between the hydrophobic pristine carbon surface and this Th2 bias, long-term in vivo safety, and performance with clinically relevant antigens were not established, and the published IL-4 ELISPOT quantitation contains an internal inconsistency as printed. The open problem addressed here synthesizes three related questions on this platform: (i) identify the innate immune mechanism by which hydrophobic pristine mesoporous carbon surfaces polarize co-delivered antigen responses toward Th2 (membrane interaction, damage-associated molecular pattern (DAMP) sensing, or other innate pathways); (ii) use that understanding to achieve a mesoporous-carbon adjuvant that elicits robust Th1/cell-mediated immunity while retaining the demonstrated favorable safety profile; and (iii) settle the immunological phenotype and long-term in vivo safety needed for translation to clinically relevant antigens, routes, and species.

Background

A vaccine adjuvant is a formulation component that boosts the immune response to a co-administered antigen. Most subunit (purified-protein) vaccines are poorly immunogenic without one, and the two-decade-old adjuvant toolbox remains narrow: aluminium salts (alum) dominantly induce Th2-type responses, while the more potent saponin-based adjuvants such as QuilA (a quillaja saponin widely used in veterinary vaccine research) carry significant toxicity. T-helper (Th) polarization describes the differentiation of CD4+ T cells into effector lineages: Th1 cells drive cell-mediated immunity (macrophage activation, cytotoxic T cells; signature cytokine interferon-gamma, IFN-gamma; mouse antibody isotype IgG2a), whereas Th2 cells support humoral immunity (signature cytokine interleukin-4, IL-4; isotype IgG1). The IgG1/IgG2a ratio in serum is a standard mouse proxy for Th2 versus Th1 dominance, and ELISPOT (an assay counting individual cytokine-secreting splenocytes as spots) quantifies IFN-gamma- and IL-4-producing cells directly. Because protection against intracellular pathogens and tumors generally requires Th1-type immunity, an adjuvant that is safe but fixed in Th2 mode has limited applicability. Nanomaterial adjuvants are attractive because they combine high antigen loading with intrinsic immunostimulation, but their action mechanisms are largely unresolved. Two prior lines shape this problem. First, Moyano et al. (2012) showed with engineered gold nanoparticles that surface hydrophobicity alone raises immune activation essentially linearly with the headgroup logP, and Seong and Matzinger (2004) proposed hydrophobicity as an ancient damage-associated molecular pattern (DAMP, i.e. an endogenous danger signal released or exposed upon cell damage that triggers innate immunity without being foreign). Neither work identified the sensing pathway, and neither addressed carbon. Second, carbon nanomaterials had shown ambivalent behavior: porous carbon particles acted as oral-vaccine adjuvants (Wang et al. 2011), while pristine carbon nanotubes show cytotoxicity and rapid payload burst release. Jambhrunkar et al. (Nano Research 2018, online 2017) synthesized pristine, unfunctionalized IMHCSs (~192 nm spheres with 15 nm mesopores and ~2.85 cm3/g pore volume, definitions: mesoporous = having pores of 2-50 nm; invaginated = folded-in hollow morphology), which load the model antigen ovalbumin (OVA) at 1,040 microgram/mg with sustained release and high macrophage uptake. In mice, OVA-loaded IMHCSs induced a 3-fold higher IgG response than OVA+QuilA (endpoint titers 6.24 x 10^6 versus 2.60 x 10^6, a ratio of about 2.4), an IgG1/IgG2a ratio of 2.0 (versus ~1 for QuilA, i.e. Th2 bias), lower in vitro toxicity than QuilA (64% versus 8% cell viability at vaccination doses), and endo-lysosomal antigen retention without cytosolic escape. However, IFN-gamma ELISPOT counts were lower than QuilA (1,108 versus 1,954 spots per million splenocytes), i.e. weaker cell-mediated potency, the paper's printed IL-4 ELISPOT values (122 versus 450 spots per million, IMHCS versus QuilA) contradict its stated 4-fold-higher IL-4 claim for IMHCS, and the mechanism of the Th2 bias was only hypothesized via the hydrophobicity-as-DAMP literature. The neighboring mesoporous-silica adjuvant literature shows that the polarization direction is material-dependent and engineerable: silica particles bias toward Th1/effector responses (Vallhov et al. 2012) and can even suppress IgE in an allergic mouse model (Kupferschmidt et al. 2014), which sharpens the unanswered question of why pristine carbon spheres do the opposite and whether that can be rationally changed without sacrificing their safety advantage.

Problem Statement

For pristine, unfunctionalized mesoporous carbon hollow sphere (IMHCS-type) vaccine adjuvants, three related questions remain open: (1) Mechanism — identify, with discriminating experimental evidence, the innate immune pathway(s) by which the hydrophobic pristine carbon surface polarizes the response to a co-delivered protein antigen toward Th2, distinguishing among the candidate routes the source work hypothesized (direct membrane interaction and membrane damage, release or exposure of damage-associated molecular patterns sensed by innate receptors, inflammasome-type or other innate sensing, versus pure antigen-delivery/depot effects); (2) Engineering — on the basis of that mechanistic understanding (or independent rational design), demonstrate a mesoporous-carbon adjuvant formulation within the pristine, unfunctionalized mesoporous-carbon platform — Th1 potency to be obtained through physical/architectural redesign (pore architecture, particle size, carbonisation temperature, graphitic character, synthesis-set surface chemistry) rather than post-synthetic chemical functionalization — that elicits robust Th1/cell-mediated immunity (IFN-gamma production and IgG2a-skewed isotype profiles benchmarked against established adjuvants such as QuilA or alum) while retaining the low toxicity that distinguishes pristine IMHCSs; (3) Immunophenotype and safety — resolve the conflicting IL-4/IFN-gamma ELISPOT quantitation in the source study (spot counts versus stated fold-changes), establish the cytokine profile (additional Th1/Th2/Th17 markers, kinetics, cellular sources) needed to define the induced immunological phenotype unambiguously, and provide the long-term in vivo safety and performance data with clinically relevant antigens, administration routes, and species required to judge translatability. The overarching objective is a mechanistically understood, Th1-capable, safe pristine-carbon adjuvant. Components (1) and (2) form the mechanistic and engineering core of the problem, and the component (3) items extend it toward translation.

References

  1. Jambhrunkar M, Yu M, Zhang H, Abbaraju P, Meka AK, Cavallaro A, Lu Y, Mitter N, Yu C. Pristine mesoporous carbon hollow spheres as safe adjuvants induce excellent Th2-biased immune response. Nano Research 11:370-382 (2018). DOI: 10.1007/s12274-017-1640-1. https://doi.org/10.1007/s12274-017-1640-1
  2. Moyano DF, Goldsmith M, Solfiell DJ, Landesman-Milo D, Miranda OR, Peer D, Rotello VM. Nanoparticle hydrophobicity dictates immune response. Journal of the American Chemical Society 134:3965-3967 (2012). DOI: 10.1021/ja2108905. https://doi.org/10.1021/ja2108905
  3. Seong S-Y, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nature Reviews Immunology 4:469-478 (2004). DOI: 10.1038/nri1372. https://doi.org/10.1038/nri1372
  4. Wang T, Zou M, Jiang H, Ji Z, Gao P, Cheng G. Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant. European Journal of Pharmaceutical Sciences 44(5):653-659 (2011). DOI: 10.1016/j.ejps.2011.10.012. https://doi.org/10.1016/j.ejps.2011.10.012
  5. Vallhov H, Kupferschmidt N, Gabrielsson S, Paulie S, Stromme M, Garcia-Bennett AE, Scheynius A. Adjuvant properties of mesoporous silica particles tune the development of effector T cells. Small 8(13):2116-2124 (2012). DOI: 10.1002/smll.201102620. https://doi.org/10.1002/smll.201102620
  6. Kupferschmidt N, Qazi KR, Kemi C, Vallhov H, Garcia-Bennett AE, Gabrielsson S, Scheynius A. Mesoporous silica particles potentiate antigen-specific T-cell responses. Nanomedicine 9(12):1835-1846 (2014). DOI: 10.2217/nnm.13.170. https://doi.org/10.2217/nnm.13.170
  7. Ghosh T, Mantri M, Gu Z, Kalantari M, Yu M, Yu C. Mesoporous carbon hollow spheres: carbonisation-temperature-dependent delivery of therapeutic proteins. Journal of Materials Chemistry B 6:763-768 (2018). DOI: 10.1039/C7TB02836A. https://doi.org/10.1039/C7TB02836A
  8. Gui X, Chen Y, Zhang Z, Lei L, Zhu F, Yang W, Guo Y, Chu M. Fluorescent hollow mesoporous carbon spheres for drug loading and tumor treatment through 980-nm laser and microwave co-irradiation. Biomaterials 248:120009 (2020). DOI: 10.1016/j.biomaterials.2020.120009. https://doi.org/10.1016/j.biomaterials.2020.120009
  9. Luo L, Liu C, He T, Zeng L, Xing J, Xia Y, Pan Y, Gong C, Wu A. Engineered fluorescent carbon dots as promising immune adjuvants to efficiently enhance cancer immunotherapy. Nanoscale 10:22035-22043 (2018). DOI: 10.1039/c8nr07252c. https://doi.org/10.1039/c8nr07252c
  10. Lei H, Alu A, Yang J, He X, He C, Ren W, Chen Z, Hong W, Chen L, He X, Yang L, Li J, Wang Z, Wang W, Wei Y, Lu S, Lu G, Song X, Wei X. Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants. Nature Communications 14:2678 (2023). DOI: 10.1038/s41467-023-38066-8. https://doi.org/10.1038/s41467-023-38066-8
  11. Wijesundara YH, Arora N, Ehrman RN, Howlett TS, Weyman TM, Trashi I, Trashi O, Kumari S, Diwakara SD, Tang W, Senarathna MC, Drewniak KH, Wang Z, Smaldone RA, Gassensmith JJ. A self-adjuvanting large pore 2D covalent organic framework as a vaccine platform. Angewandte Chemie International Edition 64:e202413020 (2025). DOI: 10.1002/anie.202413020. https://doi.org/10.1002/anie.202413020
  12. Wang X, Gao X, Wang L, Lin J, Liu Y. Advances of nanotechnology toward vaccine development against animal infectious diseases. Advanced Functional Materials 33:2305061 (2023). DOI: 10.1002/adfm.202305061. https://doi.org/10.1002/adfm.202305061
  13. Si X, Lu Y, Zha Z. Inorganic biomaterials as immunomodulators: dual strategies for activation and suppression. Science China Materials (2026, online 2026-04-08). DOI: 10.1007/s40843-025-4001-x. https://doi.org/10.1007/s40843-025-4001-x